34 results on '"López Sampalo, Almudena"'
Search Results
2. Effectiveness of a cardiac rehabilitation program on biomechanical, imaging, and physiological biomarkers in elderly patients with heart failure with preserved ejection fraction (HFpEF): FUNNEL + study protocol
- Author
-
Cuesta-Vargas, Antonio Ignacio, Fuentes-Abolafio, Iván José, García-Conejo, Celia, Díaz-Balboa, Estíbaliz, Trinidad-Fernández, Manuel, Gutiérrez-Sánchez, Daniel, Escriche-Escuder, Adrián, Cobos-Palacios, Lidia, López-Sampalo, Almudena, Pérez-Ruíz, Jose Maria, Roldán-Jiménez, Cristina, Pérez-Velasco, Miguel Angel, Mora-Robles, Javier, López-Carmona, Mª Dolores, Pérez-Cruzado, David, Martín-Martín, Jaime, and Pérez-Belmonte, Luis Miguel
- Published
- 2023
- Full Text
- View/download PDF
3. Differences in clinical features and mortality in very old unvaccinated patients (≥ 80 years) hospitalized with COVID-19 during the first and successive waves from the multicenter SEMI-COVID-19 Registry (Spain)
- Author
-
Ramos-Rincon, Jose-Manuel, Cobos-Palacios, Lidia, López-Sampalo, Almudena, Ricci, Michele, Rubio-Rivas, Manel, Nuñez-Rodriguez, Maria-Victoria, Miranda-Godoy, Rodrigo, García-Leoni, Maria-Eugenia, Fernández-Madera-Martínez, Rosa, García-García, Gema-María, Beato-Perez, Jose-Luis, Monge-Monge, Daniel, Asín-Samper, Uxua, Bustamante-Vega, Marta, Rábago-Lorite, Isabel, Freire-Castro, Santiago-Jesús, Miramontes-González, Jose-Pablo, Magallanes-Gamboa, Jeffrey-Oskar, Alcalá-Pedrajas, José-Nicolás, García-Gómez, Miriam, Cano-Llorente, Verónica, Carrasco-Sánchez, Francisco-Javier, Martinez-Carrilero, Jesús, Antón-Santos, Juan-Miguel, and Gómez-Huelgas, Ricardo
- Published
- 2022
- Full Text
- View/download PDF
4. Glucagon-like peptide-1 receptor agonists and sodium−glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect
- Author
-
Gómez-Huelgas, Ricardo, Sanz-Cánovas, Jaime, Cobos-Palacios, Lidia, López-Sampalo, Almudena, and Pérez-Belmonte, Luis M.
- Published
- 2022
- Full Text
- View/download PDF
5. A healthy lifestyle is associated with lower arterial stiffness in a metabolically healthy elderly population with overweight or obesity
- Author
-
Cobos-Palacios, Lidia, Ruiz-Moreno, Maria Isabel, Muñoz-Ubeda, Mónica, López-Sampalo, Almudena, Vilches-Perez, Alberto, Vargas-Candela, Antonio, Benitez-Porres, Javier, Navarro-Sanz, Ana, Pérez-Belmonte, Luis Miguel, Lopez-Carmona, Maria Dolores, Sanz-Canovas, Jaime, Gomez-Huelgas, Ricardo, and Bernal-Lopez, Maria Rosa
- Published
- 2022
- Full Text
- View/download PDF
6. A healthy lifestyle is associated with lower arterial stiffness in a metabolically healthy elderly population with overweight or obesity
- Author
-
Cobos-Palacios, Lidia, Moreno Ruiz, María Del Carmen, Muñoz Úbeda, Mónica, López-Sampalo, Almudena, Vilches-Perez, Alberto, Vargas-Candela, Antonio, Benítez-Porres, Javier, Navarro-Sanz, Ana, Pérez-Belmonte, Luis, Dolores,Lopez-Carmona, Sanz-Canovasa, Jaime, Gomez-Huelgasa, Ricardo, Bernal-Lopeza, Maria Rosa, Cobos-Palacios, Lidia, Moreno Ruiz, María Del Carmen, Muñoz Úbeda, Mónica, López-Sampalo, Almudena, Vilches-Perez, Alberto, Vargas-Candela, Antonio, Benítez-Porres, Javier, Navarro-Sanz, Ana, Pérez-Belmonte, Luis, Dolores,Lopez-Carmona, Sanz-Canovasa, Jaime, Gomez-Huelgasa, Ricardo, and Bernal-Lopeza, Maria Rosa
- Abstract
Depto. de Química Física, Fac. de Ciencias Químicas, TRUE, pub
- Published
- 2024
7. The Role of Heparin in Postural Orthostatic Tachycardia Syndrome and Other Post-Acute Sequelae of COVID-19.
- Author
-
Gómez-Moyano, Elisabeth, Pavón-Morón, Javier, Rodríguez-Capitán, Jorge, Bardán-Rebollar, Daniel, Ramos-Carrera, Teresa, Villalobos-Sánchez, Aurora, Pérez de Pedro, Iván, Ruiz-García, Francisco J., Mora-Robles, Javier, López-Sampalo, Almudena, Pérez-Velasco, Miguel A., Bernal-López, Maria-Rosa, Gómez-Huelgas, Ricardo, Jiménez-Navarro, Manuel, Romero-Cuevas, Miguel, Costa, Francesco, Trenas, Alicia, and Pérez-Belmonte, Luis M.
- Subjects
POSTURAL orthostatic tachycardia syndrome ,ORTHOSTATIC intolerance ,COVID-19 ,HEPARIN ,DISEASE complications ,COVID-19 treatment - Abstract
The therapeutic management and short-term consequences of the coronavirus disease 2019 (COVID-19) are well known. However, COVID-19 post-acute sequelae are less known and represent a public health problem worldwide. Patients with COVID-19 who present post-acute sequelae may display immune dysregulation, a procoagulant state, and persistent microvascular endotheliopathy that could trigger microvascular thrombosis. These elements have also been implicated in the physiopathology of postural orthostatic tachycardia syndrome, a frequent sequela in post-COVID-19 patients. These mechanisms, directly associated with post-acute sequelae, might determine the thrombotic consequences of COVID-19 and the need for early anticoagulation therapy. In this context, heparin has several potential benefits, including immunomodulatory, anticoagulant, antiviral, pro-endothelial, and vascular effects, that could be helpful in the treatment of COVID-19 post-acute sequelae. In this article, we review the evidence surrounding the post-acute sequelae of COVID-19 and the potential benefits of the use of heparin, with a special focus on the treatment of postural orthostatic tachycardia syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Manejo terapéutico de la diabetes mellitus tipo 2 en personas con edad avanzada o frágiles
- Author
-
Hernández-Negrín, Halbert, López-Sampalo, Almudena, Ricci, Michele, Velasco, Miguel Ángel Pérez, and Gómez-Huelgas, Ricardo
- Abstract
•El manejo integral de la diabetes tipo 2 en pacientes de edad avanzada o frágiles requiere una evaluación completa de su condición física, funcional y mental, así como de sus comorbilidades.•Es fundamental personalizar el tratamiento teniendo en cuenta las características individuales de cada paciente y su esperanza de vida.•Algunos grupos terapéuticos han demostrado beneficios significativos en el manejo de comorbilidades frecuentes como enfermedades cardiovasculares y renales en esta población.•Los objetivos principales del tratamiento de la diabetes en el paciente mayor debe ser preservar la calidad de vida, mantener la capacidad funcional y evitar las hipoglucemias.•Los avances en la monitorización continua de glucosa ofrecen nuevas oportunidades para mejorar el manejo de la diabetes y reducir complicaciones en personas de edad avanzada.•La simplificación del tratamiento antidiabético puede estar indicada en pacientes mayores con un estado de salud complejo, para reducir la carga del cuidador y evitar efectos adversos de la medicación.•Es necesario realizar evaluaciones periódicas y ajustes individualizados en el tratamiento de la diabetes tipo 2 en pacientes de edad avanzada o frágiles, buscando un equilibrio entre beneficios terapéuticos y riesgos potenciales.
- Published
- 2024
- Full Text
- View/download PDF
9. Remission of type 2 diabetes: A critical appraisal
- Author
-
Ricci, Michele, primary, Mancebo-Sevilla, Juan José, additional, Cobos Palacios, Lidia, additional, Sanz-Cánovas, Jaime, additional, López-Sampalo, Almudena, additional, Hernández-Negrin, Halbert, additional, Pérez-Velasco, Miguel Angel, additional, Pérez-Belmonte, Luis M., additional, Bernal-López, Maria Rosa, additional, and Gómez-Huelgas, Ricardo, additional
- Published
- 2023
- Full Text
- View/download PDF
10. COVID-19 in Older Patients: Assessment of Post-COVID-19 Sarcopenia
- Author
-
López-Sampalo, Almudena, primary, Cobos-Palacios, Lidia, additional, Vilches-Pérez, Alberto, additional, Sanz-Cánovas, Jaime, additional, Vargas-Candela, Antonio, additional, Mancebo-Sevilla, Juan José, additional, Hernández-Negrín, Halbert, additional, Gómez-Huelgas, Ricardo, additional, and Bernal-López, María Rosa, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases
- Author
-
Sanz-Cánovas, Jaime, primary, Ricci, Michele, primary, Cobos-Palacios, Lidia, primary, López-Sampalo, Almudena, primary, Hernández-Negrín, Halbert, primary, Vázquez-Márquez, María, primary, Mancebo-Sevilla, Juan José, primary, Álvarez-Recio, Elena, primary, López-Carmona, María Dolores, primary, Pérez-Velasco, Miguel Ángel, primary, Pérez-Belmonte, Luis Miguel, primary, Gómez-Huelgas, Ricardo, primary, and Bernal-López, Maria-Rosa, primary
- Published
- 2023
- Full Text
- View/download PDF
12. Obesity, Diabetes, and Cardiovascular Risk Burden in Systemic Lupus Erythematosus: Current Approaches and Knowledge Gaps—A Rapid Scoping Review
- Author
-
Hernández-Negrín, Halbert, primary, Ricci, Michele, additional, Mancebo-Sevilla, Juan José, additional, Sanz-Cánovas, Jaime, additional, López-Sampalo, Almudena, additional, Cobos-Palacios, Lidia, additional, Romero-Gómez, Carlos, additional, Pérez de Pedro, Iván, additional, Ayala-Gutiérrez, María del Mar, additional, Gómez-Huelgas, Ricardo, additional, and Bernal-López, María Rosa, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Clinical Features and Risk Factors for Mortality Among Long-term Care Facility Residents Hospitalized Due to COVID-19 in Spain
- Author
-
Ramos-Rincón, José-Manuel, Bernabeu-Wittel, Máximo, Fiteni-Mera, Isabel, López-Sampalo, Almudena, López-Ríos, Carmen, García-Andreu, María-Del-Mar, Mancebo-Sevilla, Juan-José, Jiménez-Juan, Carlos, Matía-Sanz, Marta, López-Quirantes, Pablo, Rubio-Rivas, Manuel, Paredes-Ruiz, Diana, González-San-Narciso, Candela, González-Vega, Rocío, Sanz-Espinosa, Pablo, Hernández-Milián, Almudena, Gonzalez-Noya, Amara, Gil-Sánchez, Ricardo, Boixeda, Ramon, Alcalá-Pedrajas, José-Nicolás, Palop-Cervera, Marta, Cortés-Rodríguez, Begoña, Guisado-Espartero, María-Esther, Mella-Pérez, Carmen, Gómez-Huelgas, Ricardo, and SEMI-COVID-19 Network
- Subjects
Male ,Aging ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Epidemiology ,Nursing homes ,Logistic regression ,Risk Factors ,Internal medicine ,medicine ,Humans ,Dementia ,Mortality ,Aged ,Retrospective Studies ,business.industry ,Mortality rate ,COVID-19 ,Retrospective cohort study ,medicine.disease ,Long-Term Care ,Hospitalization ,Long-term care ,Cross-Sectional Studies ,Risk factors ,Spain ,COVID-19, epidemiology, mortality, nursing homes, risk factors ,Female ,Functional status ,Geriatrics and Gerontology ,business - Abstract
Background COVID-19 severely impacted older adults and long-term care facility (LTCF) residents. Our primary aim was to describe differences in clinical and epidemiological variables, in-hospital management, and outcomes between LTCF residents and community-dwelling older adults hospitalized with COVID-19. The secondary aim was to identify risk factors for mortality due to COVID-19 in hospitalized LTCF residents. Methods This is a cross-sectional analysis within a retrospective cohort of hospitalized patients ≥75 years with confirmed COVID-19 admitted to 160 Spanish hospitals. Differences between groups and factors associated with mortality among LTCF residents were assessed through comparisons and logistic regression analysis. Results Of 6 189 patients ≥75 years, 1 185 (19.1%) were LTCF residents and 4 548 (73.5%) were community-dwelling. LTCF residents were older (median: 87.4 vs 82.1 years), mostly female (61.6% vs 43.2%), had more severe functional dependence (47.0% vs 7.8%), more comorbidities (Charlson Comorbidity Index: 6 vs 5), had dementia more often (59.1% vs 14.4%), and had shorter duration of symptoms (median: 3 vs 6 days) than community-dwelling patients (all, p < .001). Mortality risk factors in LTCF residents were severe functional dependence (adjusted odds ratios [aOR]: 1.79; 95% confidence interval [CI]: 1.13–2.83; p = .012), dyspnea (1.66; 1.16–2.39; p = .004), SatO2 < 94% (1.73; 1.27–2.37; p = .001), temperature ≥ 37.8°C (1.62; 1.11–2.38; p = .013); qSOFA index ≥ 2 (1.62; 1.11–2.38; p = .013), bilateral infiltrates (1.98; 1.24–2.98; p < .001), and high C-reactive protein (1.005; 1.003–1.007; p < .001). In-hospital mortality was initially higher among LTCF residents (43.3% vs 39.7%), but lower after adjusting for sex, age, functional dependence, and comorbidities (aOR: 0.74, 95%CI: 0.62–0.87; p < .001). Conclusion Basal functional status and COVID-19 severity are risk factors of mortality in LTCF residents. The lower adjusted mortality rate in LTCF residents may be explained by earlier identification, treatment, and hospitalization for COVID-19.
- Published
- 2021
14. Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
- Author
-
Pérez-Belmonte, Luis M, Sanz-Cánovas, Jaime, García de Lucas, María D, Ricci, Michele, Avilés-Bueno, Beatriz, Cobos-Palacios, Lidia, Pérez-Velasco, Miguel A, López-Sampalo, Almudena, Bernal-López, M Rosa, Jansen-Chaparro, Sergio, Miramontes-González, José P, and Gómez-Huelgas, Ricardo
- Subjects
Heart Failure ,obesity ,semaglutide ,Diabetes Mellitus, Type 2 ,Endocrinology, Diabetes and Metabolism ,Glucagon-Like Peptides ,Humans ,health status ,type 2 diabetes ,Obesity ,Glucagon-Like Peptide-1 Receptor ,Retrospective Studies - Abstract
BackgroundThe impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure.MethodsIn this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.ResultsA total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, pConclusionIn obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.
- Published
- 2022
15. C-Reactive Protein and Serum Albumin Ratio: A Feasible Prognostic Marker in Hospitalized Patients with COVID-19
- Author
-
Giner Galvañ, Vicente, Pomares Gómez, Francisco, Quesada, José, Rubio Rivas, Manuel, Tejada Montes, Javier, Baltasar Corral, Jesús, Taboada-Martínez, María Luisa, Sánchez Mesa, Blanca, Arnalich Fernández, Francisco, Corral Beamonte, Esther del, López Sampalo, Almudena, Pesqueira Fontán, Paula, Fernández Garcés, Mar, Gómez Huelgas, Ricardo, Ramos Rincón, José, and SEMI-COVID-19 Network
- Subjects
COVID-19 ,serum albumin ,C-reactive protein ,prognosis ,syndemic ,comorbidity ,Comorbiditat ,Medicine (miscellaneous) ,Comorbidity ,General Biochemistry, Genetics and Molecular Biology - Abstract
(1) Background: C-reactive protein (CRP) and albumin are inflammatory markers. We analyzed the prognostic capacity of serum albumin (SA) and CRP for an outcome comprising mortality, length of stay, ICU admission, and non-invasive mechanical ventilation in hospitalized COVID-19 patients. (2) Methods: We conducted a retrospective cohort study based on the Spanish national SEMI-COVID-19 Registry. Two multivariate logistic models were adjusted for SA, CRP, and their combination. Training and testing samples were used to validate the models. (3) Results: The outcome was present in 41.1% of the 3471 participants, who had lower SA (mean [SD], 3.5 [0.6] g/dL vs. 3.8 [0.5] g/dL; p < 0.001) and higher CRP (108.9 [96.5] mg/L vs. 70.6 [70.3] mg/L; p < 0.001). In the adjusted multivariate model, both were associated with poorer evolution: SA, OR 0.674 (95% CI, 0.551–0.826; p < 0.001); CRP, OR 1.002 (95% CI, 1.001–1.004; p = 0.003). The CRP/SA model had a similar predictive capacity (honest AUC, 0.8135 [0.7865–0.8405]), with a continuously increasing risk and cutoff value of 25 showing the highest predictive capacity (OR, 1.470; 95% CI, 1.188–1.819; p < 0.001). (4) Conclusions: SA and CRP are good independent predictors of patients hospitalized with COVID-19. For the CRP/SA ratio value, 25 is the cutoff for poor clinical course.
- Published
- 2022
16. Management of Type 2 Diabetes Mellitus in Elderly Patients with Frailty and/or Sarcopenia
- Author
-
Sanz-Cánovas, Jaime, primary, López-Sampalo, Almudena, additional, Cobos-Palacios, Lidia, additional, Ricci, Michele, additional, Hernández-Negrín, Halbert, additional, Mancebo-Sevilla, Juan José, additional, Álvarez-Recio, Elena, additional, López-Carmona, María Dolores, additional, Pérez-Belmonte, Luis Miguel, additional, Gómez-Huelgas, Ricardo, additional, and Bernal-López, Maria Rosa, additional
- Published
- 2022
- Full Text
- View/download PDF
17. Ethnicity and Clinical Outcomes in Patients Hospitalized for COVID-19 in Spain: Results from the Multicenter SEMI-COVID-19 Registry
- Author
-
Ramos Rincón, José Manuel, Cobos Palacios, Lidia, López Sampalo, Almudena, Ricci, Michele, Rubio-Rivas, Manuel, Martos Pérez, Francisco, Barón-Franco, Bosco, Gómez Huelgas, Ricardo, and Universidad de Sevilla. Departamento de Medicina
- Subjects
SARS-CoV-2 ,Spain ,minority groups ,COVID-19 ,migrants ,ethnic groups - Abstract
Background: This work aims to analyze clinical outcomes according to ethnic groups in patients hospitalized for COVID-19 in Spain. (2) Methods: This nationwide, retrospective, multicenter, observational study analyzed hospitalized patients with confirmed COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry) from 1 March 2020 to 31 December 2021. Clinical outcomes were assessed according to ethnicity (Latin Americans, Sub-Saharan Africans, Asians, North Africans, Europeans). The outcomes were in-hospital mortality (IHM), intensive care unit (ICU) admission, and the use of invasive mechanical ventilation (IMV). Associations between ethnic groups and clinical outcomes adjusted for patient characteristics and baseline Charlson Comorbidity Index values and wave were evaluated using logistic regression. (3) Results: Of 23,953 patients (median age 69.5 years, 42.9% women), 7.0% were Latin American, 1.2% were North African, 0.5% were Asian, 0.5% were Sub-Saharan African, and 89.7% were European. Ethnic minority patients were significantly younger than European patients (median (IQR) age 49.1 (40.5–58.9) to 57.1 (44.1–67.1) vs. 71.5 (59.5–81.4) years, p < 0.001). The unadjusted IHM was higher in European (21.6%) versus North African (11.4%), Asian (10.9%), Latin American (7.1%), and Sub-Saharan African (3.2%) patients. After further adjustment, the IHM was lower in Sub-Saharan African (OR 0.28 (0.10–0.79), p = 0.017) versus European patients, while ICU admission rates were higher in Latin American and North African versus European patients (OR (95%CI) 1.37 (1.17–1.60), p < 0.001) and (OR (95%CI) 1.74 (1.26–2.41), p < 0.001). Moreover, Latin American patients were 39% more likely than European patients to use IMV (OR (95%CI) 1.43 (1.21–1.71), p < 0.001). (4) Conclusion: The adjusted IHM was similar in all groups except for Sub-Saharan Africans, who had lower IHM. Latin American patients were admitted to the ICU and required IMV more often. 10.3390/jcm11071949
- Published
- 2022
18. Ethnicity and Clinical Outcomes in Patients Hospitalized for COVID-19 in Spain: Results from the Multicenter SEMI-COVID-19 Registry
- Author
-
Universidad de Sevilla. Departamento de Medicina, Ramos Rincón, José Manuel, Cobos Palacios, Lidia, López Sampalo, Almudena, Ricci, Michele, Rubio-Rivas, Manuel, Martos Pérez, Francisco, Barón-Franco, Bosco, Gómez Huelgas, Ricardo, Universidad de Sevilla. Departamento de Medicina, Ramos Rincón, José Manuel, Cobos Palacios, Lidia, López Sampalo, Almudena, Ricci, Michele, Rubio-Rivas, Manuel, Martos Pérez, Francisco, Barón-Franco, Bosco, and Gómez Huelgas, Ricardo
- Abstract
Background: This work aims to analyze clinical outcomes according to ethnic groups in patients hospitalized for COVID-19 in Spain. (2) Methods: This nationwide, retrospective, multicenter, observational study analyzed hospitalized patients with confirmed COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry) from 1 March 2020 to 31 December 2021. Clinical outcomes were assessed according to ethnicity (Latin Americans, Sub-Saharan Africans, Asians, North Africans, Europeans). The outcomes were in-hospital mortality (IHM), intensive care unit (ICU) admission, and the use of invasive mechanical ventilation (IMV). Associations between ethnic groups and clinical outcomes adjusted for patient characteristics and baseline Charlson Comorbidity Index values and wave were evaluated using logistic regression. (3) Results: Of 23,953 patients (median age 69.5 years, 42.9% women), 7.0% were Latin American, 1.2% were North African, 0.5% were Asian, 0.5% were Sub-Saharan African, and 89.7% were European. Ethnic minority patients were significantly younger than European patients (median (IQR) age 49.1 (40.5–58.9) to 57.1 (44.1–67.1) vs. 71.5 (59.5–81.4) years, p < 0.001). The unadjusted IHM was higher in European (21.6%) versus North African (11.4%), Asian (10.9%), Latin American (7.1%), and Sub-Saharan African (3.2%) patients. After further adjustment, the IHM was lower in Sub-Saharan African (OR 0.28 (0.10–0.79), p = 0.017) versus European patients, while ICU admission rates were higher in Latin American and North African versus European patients (OR (95%CI) 1.37 (1.17–1.60), p < 0.001) and (OR (95%CI) 1.74 (1.26–2.41), p < 0.001). Moreover, Latin American patients were 39% more likely than European patients to use IMV (OR (95%CI) 1.43 (1.21–1.71), p < 0.001). (4) Conclusion: The adjusted IHM was similar in all groups except for Sub-Saharan Africans, who had lower IHM. Latin American patients were admitted to the ICU and required IMV more often.
- Published
- 2022
19. Additional file 1 of Differences in clinical features and mortality in very old unvaccinated patients (≥ 80 years) hospitalized with COVID-19 during the first and successive waves from the multicenter SEMI-COVID-19 Registry (Spain)
- Author
-
Ramos-Rincon, Jose-Manuel, Cobos-Palacios, Lidia, López-Sampalo, Almudena, Ricci, Michele, Rubio-Rivas, Manel, Nuñez-Rodriguez, Maria-Victoria, Miranda-Godoy, Rodrigo, García-Leoni, Maria-Eugenia, Fernández-Madera-Martínez, Rosa, García-García, Gema-María, Beato-Perez, Jose-Luis, Monge-Monge, Daniel, Asín-Samper, Uxua, Bustamante-Vega, Marta, Rábago-Lorite, Isabel, Freire-Castro, Santiago-Jesús, Miramontes-González, Jose-Pablo, Magallanes-Gamboa, Jeffrey-Oskar, Alcalá-Pedrajas, José-Nicolás, García-Gómez, Miriam, Cano-Llorente, Verónica, Carrasco-Sánchez, Francisco-Javier, Martinez-Carrilero, Jesús, Antón-Santos, Juan-Miguel, and Gómez-Huelgas, Ricardo
- Abstract
Additional file 1. List of the SEMI-COVID-19 Network members.
- Published
- 2022
- Full Text
- View/download PDF
20. Ethnicity and Clinical Outcomes in Patients Hospitalized for COVID-19 in Spain: Results from the Multicenter SEMI-COVID-19 Registry
- Author
-
Ramos-Rincón, José Manuel, Cobos-Palacios, Lidia, López-Sampalo, Almudena, Ricci, Michele, Rubio-Rivas, Manuel, Martos-Pérez, Francisco, Lalueza-Blanco, Antonio, Moragón-Ledesma, Sergio, Fonseca-Aizpuru, Eva-María, García-García, Gema-María, Beato-Pérez, José-Luis, Josa-Laorden, Claudia, Arnalich-Fernández, Francisco, Molinos-Castro, Sonia, Torres‑Peña, J.D., Artero, Arturo, Vargas-Núñez, Juan-Antonio, Méndez-Bailón, Manuel, Loureiro-Amigo, Jose, Hernández-Garrido, María-Soledad, Peris-García, Jorge, López-Reboiro, Manuel-Lorenzo, Barón-Franco, Bosco, Casas-Rojo, José Manuel, Gómez-Huelgas, Ricardo, and SEMI‐COVID‐19 Network
- Subjects
SARS-CoV-2 ,Spain ,Minority groups ,COVID-19 ,General Medicine ,Grups ètnics ,ethnic groups ,minority groups ,migrants ,Ethnic groups ,Migrants - Abstract
(1) Background: This work aims to analyze clinical outcomes according to ethnic groups in patients hospitalized for COVID-19 in Spain. (2) Methods: This nationwide, retrospective, multicenter, observational study analyzed hospitalized patients with confirmed COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry) from 1 March 2020 to 31 December 2021. Clinical outcomes were assessed according to ethnicity (Latin Americans, Sub-Saharan Africans, Asians, North Africans, Europeans). The outcomes were in-hospital mortality (IHM), intensive care unit (ICU) admission, and the use of invasive mechanical ventilation (IMV). Associations between ethnic groups and clinical outcomes adjusted for patient characteristics and baseline Charlson Comorbidity Index values and wave were evaluated using logistic regression. (3) Results: Of 23,953 patients (median age 69.5 years, 42.9% women), 7.0% were Latin American, 1.2% were North African, 0.5% were Asian, 0.5% were Sub-Saharan African, and 89.7% were European. Ethnic minority patients were significantly younger than European patients (median (IQR) age 49.1 (40.5–58.9) to 57.1 (44.1–67.1) vs. 71.5 (59.5–81.4) years, p < 0.001). The unadjusted IHM was higher in European (21.6%) versus North African (11.4%), Asian (10.9%), Latin American (7.1%), and Sub-Saharan African (3.2%) patients. After further adjustment, the IHM was lower in Sub-Saharan African (OR 0.28 (0.10–0.79), p = 0.017) versus European patients, while ICU admission rates were higher in Latin American and North African versus European patients (OR (95%CI) 1.37 (1.17–1.60), p < 0.001) and (OR (95%CI) 1.74 (1.26–2.41), p < 0.001). Moreover, Latin American patients were 39% more likely than European patients to use IMV (OR (95%CI) 1.43 (1.21–1.71), p < 0.001). (4) Conclusion: The adjusted IHM was similar in all groups except for Sub-Saharan Africans, who had lower IHM. Latin American patients were admitted to the ICU and required IMV more often.
- Published
- 2022
21. Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure
- Author
-
Pérez‐Belmonte, Luis M., primary, Sanz‐Cánovas, Jaime, additional, Millán‐Gómez, Mercedes, additional, Osuna‐Sánchez, Julio, additional, López‐Sampalo, Almudena, additional, Ricci, Michele, additional, Jiménez‐Navarro, Manuel, additional, López‐Carmona, Maria D., additional, Bernal‐López, María Rosa, additional, Barbancho, Miguel A., additional, Lara, José P., additional, and Gómez‐Huelgas, Ricardo, additional
- Published
- 2021
- Full Text
- View/download PDF
22. Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.
- Author
-
Ramos-Rincon, Jose-Manuel, López-Carmona, María-Dolores, Cobos-Palacios, Lidia, López-Sampalo, Almudena, Rubio-Rivas, Manuel, Martín-Escalante, María-Dolores, de-Cossio-Tejido, Santiago, Taboada-Martínez, María-Luisa, Muiño-Miguez, Antonio, Areses-Manrique, Maria, Martinez-Cilleros, Carmen, Tuñón-de-Almeida, Carlota, Abella-Vázquez, Lucy, Martínez-Gonzalez, Angel-Luís, Díez-García, Luis-Felipe, Ripper, Carlos-Jorge, Asensi, Victor, Martinez-Pascual, Angeles, Guisado-Vasco, Pablo, and Lumbreras-Bermejo, Carlos
- Subjects
OLDER patients ,REMDESIVIR ,COVID-19 ,MORTALITY ,DEATH rate - Abstract
(1) Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2) Methods: This is a retrospective analysis of patients ≥ 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. (3) Results: Of the 4331 patients admitted, 1312 (30.3%) were ≥80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29–0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22–0.61) (p < 0.001)). (4) Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. C-Reactive Protein and Serum Albumin Ratio: A Feasible Prognostic Marker in Hospitalized Patients with COVID-19.
- Author
-
Giner-Galvañ, Vicente, Pomares-Gómez, Francisco José, Quesada, José Antonio, Rubio-Rivas, Manuel, Tejada-Montes, Javier, Baltasar-Corral, Jesús, Taboada-Martínez, María Luisa, Sánchez-Mesa, Blanca, Arnalich-Fernández, Francisco, Del Corral-Beamonte, Esther, López-Sampalo, Almudena, Pesqueira-Fontán, Paula María, Fernández-Garcés, Mar, Gómez-Huelgas, Ricardo, and Ramos-Rincón, José Manuel
- Subjects
BLOOD proteins ,SERUM albumin ,COVID-19 ,C-reactive protein ,PROGNOSIS - Abstract
(1) Background: C-reactive protein (CRP) and albumin are inflammatory markers. We analyzed the prognostic capacity of serum albumin (SA) and CRP for an outcome comprising mortality, length of stay, ICU admission, and non-invasive mechanical ventilation in hospitalized COVID-19 patients. (2) Methods: We conducted a retrospective cohort study based on the Spanish national SEMI-COVID-19 Registry. Two multivariate logistic models were adjusted for SA, CRP, and their combination. Training and testing samples were used to validate the models. (3) Results: The outcome was present in 41.1% of the 3471 participants, who had lower SA (mean [SD], 3.5 [0.6] g/dL vs. 3.8 [0.5] g/dL; p < 0.001) and higher CRP (108.9 [96.5] mg/L vs. 70.6 [70.3] mg/L; p < 0.001). In the adjusted multivariate model, both were associated with poorer evolution: SA, OR 0.674 (95% CI, 0.551–0.826; p < 0.001); CRP, OR 1.002 (95% CI, 1.001–1.004; p = 0.003). The CRP/SA model had a similar predictive capacity (honest AUC, 0.8135 [0.7865–0.8405]), with a continuously increasing risk and cutoff value of 25 showing the highest predictive capacity (OR, 1.470; 95% CI, 1.188–1.819; p < 0.001). (4) Conclusions: SA and CRP are good independent predictors of patients hospitalized with COVID-19. For the CRP/SA ratio value, 25 is the cutoff for poor clinical course. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Clinical Features and Risk Factors for Mortality Among Long-term Care Facility Residents Hospitalized Due to COVID-19 in Spain.
- Author
-
Ramos-Rincón, José-Manuel, Bernabeu-Wittel, Máximo, Fiteni-Mera, Isabel, López-Sampalo, Almudena, López-Ríos, Carmen, García-Andreu, María-del-Mar, Mancebo-Sevilla, Juan-José, Jiménez-Juan, Carlos, Matía-Sanz, Marta, López-Quirantes, Pablo, Rubio-Rivas, Manuel, Paredes-Ruiz, Diana, González-San-Narciso, Candela, González-Vega, Rocío, Sanz-Espinosa, Pablo, Hernández-Milián, Almudena, Gonzalez-Noya, Amara, Gil-Sánchez, Ricardo, Boixeda, Ramon, and Alcalá-Pedrajas, José-Nicolás
- Subjects
MORTALITY risk factors ,LONG-term care facilities ,ADULT care facilities ,COVID-19 ,OLDER people - Abstract
Background: COVID-19 severely impacted older adults and long-term care facility (LTCF) residents. Our primary aim was to describe differences in clinical and epidemiological variables, in-hospital management, and outcomes between LTCF residents and community-dwelling older adults hospitalized with COVID-19. The secondary aim was to identify risk factors for mortality due to COVID-19 in hospitalized LTCF residents.Methods: This is a cross-sectional analysis within a retrospective cohort of hospitalized patients ≥75 years with confirmed COVID-19 admitted to 160 Spanish hospitals. Differences between groups and factors associated with mortality among LTCF residents were assessed through comparisons and logistic regression analysis.Results: Of 6 189 patients ≥75 years, 1 185 (19.1%) were LTCF residents and 4 548 (73.5%) were community-dwelling. LTCF residents were older (median: 87.4 vs 82.1 years), mostly female (61.6% vs 43.2%), had more severe functional dependence (47.0% vs 7.8%), more comorbidities (Charlson Comorbidity Index: 6 vs 5), had dementia more often (59.1% vs 14.4%), and had shorter duration of symptoms (median: 3 vs 6 days) than community-dwelling patients (all, p < .001). Mortality risk factors in LTCF residents were severe functional dependence (adjusted odds ratios [aOR]: 1.79; 95% confidence interval [CI]: 1.13-2.83; p = .012), dyspnea (1.66; 1.16-2.39; p = .004), SatO2 < 94% (1.73; 1.27-2.37; p = .001), temperature ≥ 37.8°C (1.62; 1.11-2.38; p = .013); qSOFA index ≥ 2 (1.62; 1.11-2.38; p = .013), bilateral infiltrates (1.98; 1.24-2.98; p < .001), and high C-reactive protein (1.005; 1.003-1.007; p < .001). In-hospital mortality was initially higher among LTCF residents (43.3% vs 39.7%), but lower after adjusting for sex, age, functional dependence, and comorbidities (aOR: 0.74, 95%CI: 0.62-0.87; p < .001).Conclusion: Basal functional status and COVID-19 severity are risk factors of mortality in LTCF residents. The lower adjusted mortality rate in LTCF residents may be explained by earlier identification, treatment, and hospitalization for COVID-19. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
25. Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.
- Author
-
Pérez‐Belmonte, Luis M., Sanz‐Cánovas, Jaime, Millán‐Gómez, Mercedes, Osuna‐Sánchez, Julio, López‐Sampalo, Almudena, Ricci, Michele, Jiménez‐Navarro, Manuel, López‐Carmona, Maria D., Bernal‐López, María Rosa, Barbancho, Miguel A., Lara, José P., and Gómez‐Huelgas, Ricardo
- Subjects
OLDER people with diabetes ,SODIUM-glucose cotransporters ,DRUG efficacy ,DIURETICS ,SCIENTIFIC observation ,EMPAGLIFLOZIN ,URINE ,TYPE 2 diabetes ,INSULIN ,HOSPITAL care ,HEART failure ,PHARMACODYNAMICS ,DISEASE complications ,OLD age - Abstract
Background: There is little evidence on the use of sodium−glucose cotransporter 2 (SGLT2) inhibitors in older patients with heart failure. This work analyzed the clinical efficacy and safety of empagliflozin continuation in very old patients with type 2 diabetes hospitalized for acute decompensated heart failure. Methods: We conducted a real‐world observational study between September 2015 and June 2021. Patients ≥80 years were grouped by antihyperglycemic regimen: (1) continuation of preadmission empagliflozin combined with basal insulin regimen and (2) conventional basal‐bolus insulin regimen. A propensity score matching analysis matched patients in both groups in a 1:1 manner. The primary outcome was differences in clinical efficacy measured by the visual analogue scale dyspnea score, NT‐proBNP levels, diuretic response, and cumulative urine output. Safety endpoints such as adverse events, worsening heart failure, discontinuation of empagliflozin, length of hospital stay, and in‐hospital deaths were also analyzed. Results: After propensity score matching, 79 patients were included in each group. At discharge, the N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) levels were lower in the empagliflozin continuation group than in the insulin group (1699 ± 522 vs. 2303 ± 598 pg/ml, p = 0.021). Both the diuretic response and cumulative urine output were greater in patients treated with empagliflozin than in patients with basal‐bolus insulin during the hospitalization (at discharge: −0.14 ± −0.06 vs. −0.24 ± −0.10, p = 0.044; and 16,100 ± 1510 vs. 13,900 ± 1220 ml, p = 0.037, respectively). No differences were observed in safety outcomes. Conclusions: In very old patients with type 2 diabetes hospitalized for acute heart failure, continuing preadmission empagliflozin reduced NT‐proBNP levels and increased diuretic response and urine output compared to a basal‐bolus insulin regimen. The empagliflozin regimen also showed a good safety profile. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19
- Author
-
Rubio-Rivas, Manuel, primary, Corbella, Xavier, additional, Mora-Luján, José María, additional, Loureiro-Amigo, Jose, additional, López Sampalo, Almudena, additional, Yera Bergua, Carmen, additional, Esteve Atiénzar, Pedro Jesús, additional, Díez García, Luis Felipe, additional, Gonzalez Ferrer, Ruth, additional, Plaza Canteli, Susana, additional, Pérez Piñeiro, Antía, additional, Cortés Rodríguez, Begoña, additional, Jorquer Vidal, Leyre, additional, Pérez Catalán, Ignacio, additional, León Téllez, Marta, additional, Martín Oterino, José Ángel, additional, Martín González, María Candelaria, additional, Serrano Carrillo de Albornoz, José Luis, additional, García Sardon, Eva, additional, Alcalá Pedrajas, José Nicolás, additional, Martin-Urda Diez-Canseco, Anabel, additional, Esteban Giner, María José, additional, Tellería Gómez, Pablo, additional, Ramos-Rincón, José Manuel, additional, and Gómez-Huelgas, Ricardo, additional
- Published
- 2020
- Full Text
- View/download PDF
27. Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain
- Author
-
Pérez-Belmonte, Luis M., primary, López-Carmona, María D., additional, Quevedo-Marín, Juan L., additional, Ricci, Michele, additional, Martín-Carmona, Jesica, additional, Sanz-Cánovas, Jaime, additional, López-Sampalo, Almudena, additional, Martín-Escalante, María D., additional, Bernal-López, M. Rosa., additional, and Gómez-Huelgas, Ricardo, additional
- Published
- 2020
- Full Text
- View/download PDF
28. Incidence of hypercalcemia and its causes in spain in a fifteen years period (2001–2015)
- Author
-
Ropero-Luis, Guillermo, primary, Sanz-Cánovas, Jaime, additional, López-Sampalo, Almudena, additional, Gómez-Huelgas, Ricardo, additional, and Ruiz-Cantero, Alberto, additional
- Published
- 2020
- Full Text
- View/download PDF
29. Time to rethink the role of sodium-glucose co-transporter 2 inhibitors in the elderly. Authors' reply
- Author
-
Gómez-Huelgas, Ricardo, primary, Pérez‑Belmonte, Luis M., additional, López‑Sampalo, Almudena, additional, Morilla‑Herrera, Juan C., additional, Bellosta‑Ymbert, José M., additional, and Bernal‑López, M. Rosa, additional
- Published
- 2019
- Full Text
- View/download PDF
30. Patología psiquiátrica e ingesta de agua: no siempre es polidipsia psicógena
- Author
-
Ropero-Luis, Guillermo, primary, Muñoz-Sánchez, Ana, additional, López-Sampalo, Almudena, additional, Mancebo-Sevilla, Juan-José, additional, and Gómez-Huelgas, Ricardo, additional
- Published
- 2018
- Full Text
- View/download PDF
31. Diabetes tipo 2 en paciente anciano
- Author
-
López-Sampalo, Almudena, primary, Cobos-Palacios, Lidia, additional, Costo-Muriel, Clara, additional, Jansen-Chaparro, Sergio, additional, and Gómez-Huelgas, Ricardo, additional
- Published
- 2018
- Full Text
- View/download PDF
32. Impacto de la fragilidad en la supervivencia intrahospitalaria en pacientes mayores con infección por COVID-19: la importancia de su identificación temprana. Registro Nacional SEMI-COVID
- Author
-
López-Sampalo, Almudena, Hernández-Negrín, Halbert, Bernal-López, Maria Rosa, Rubio-Rivas, Manuel, Martín-Escalante, Maria Dolores, Wikman-Jogersen, Philip, García-Reyne, Ana, Martinez, Rosa Fernández-Madera, Gómez-Antúnez, María, Luis Beato-Pérez, José, David Torres-Peña, José, Ángel Martín-Oterino, José, Loureiro-Amigo, Jose, de la Sota, Juan Vicente, Gil-Sanchez, Ricardo, Reboiro, Manuel Lorenzo-López, Bernal-Román, Berta, Fernández-Sola, Joaquin, Amorós-Martínez, Francisco, Vicente-López, Natalia, Valle-Bernard, Reina, López-Ruiz, Antonio, Ramos-Rincón, José-Manuel, and Gómez-Huelgas, Ricardo
- Abstract
Background: Emerging evidence suggests that frailty may be a significant predictor of poor outcomes in older individuals hospitalized due to COVID-19. This study aims to determine the prognostic value of frailty on intrahospital patient survival. Methods: This observational, multicenter, nationwide study included patients aged 70 years and older who were hospitalized due to COVID-19 in Spain between March 1 and December 31, 2020. Patient data were obtained from the SEMI-COVID-19 Registry of the Spanish Society of Internal Medicine. Frailty was assessed using the Clinical Frailty Scale. The primary outcome was hospital survival. Cox proportional hazards models were used to assess predictors of survival. Results: A total of 1,878 participants (52% men and 48% women) were included, with 1,351 (71.9%) survivors and 527 (28.1%) non-survivors. The non-survivor group had higher mean age (83.5 vs. 81 years), comorbidities (6.3 vs. 5.3 points on the Charlson index), degree of dependency (26.8% vs. 12.4% severely dependent patients), and frailty (34.5% vs. 14.7% severely frail patients) compared to survivors. However, there were no differences in terms of sex. Our results demonstrate that a moderate-severe degree of frailty is the primary factor independently associated with shorter survival [HR 2.344 (1.437-3.823; p <0.001) for CFS 5-6 and 3.694 (2.155-6.330; p <0.001) for CFS 7-9]. Conclusion: Frailty is the main predictor of adverse outcomes in older patients with COVID-19. The utilization of tools such as the Clinical Frailty Scale is crucial for early detection in this population.
- Published
- 2023
- Full Text
- View/download PDF
33. Authors' reply.
- Author
-
Gómez-Huelgas, Ricardo, Pérez-Belmonte, Luis M., López-Sampalo, Almudena, Morilla-Herrera, Juan C., Bellosta-Ymbert, José M., and Bernal-López, M. Rosa
- Published
- 2019
- Full Text
- View/download PDF
34. Ethnicity and Clinical Outcomes in Patients Hospitalized for COVID-19 in Spain: Results from the Multicenter SEMI-COVID-19 Registry.
- Author
-
Ramos-Rincon JM, Cobos-Palacios L, López-Sampalo A, Ricci M, Rubio-Rivas M, Martos-Pérez F, Lalueza-Blanco A, Moragón-Ledesma S, Fonseca-Aizpuru EM, García-García GM, Beato-Perez JL, Josa-Laorden C, Arnalich-Fernández F, Molinos-Castro S, Torres-Peña JD, Artero A, Vargas-Núñez JA, Mendez-Bailon M, Loureiro-Amigo J, Hernández-Garrido MS, Peris-García J, López-Reboiro ML, Barón-Franco B, Casas-Rojo JM, Gómez-Huelgas R, and On Behalf Of The Semi-Covid-Network
- Abstract
(1) Background: This work aims to analyze clinical outcomes according to ethnic groups in patients hospitalized for COVID-19 in Spain. (2) Methods: This nationwide, retrospective, multicenter, observational study analyzed hospitalized patients with confirmed COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry) from 1 March 2020 to 31 December 2021. Clinical outcomes were assessed according to ethnicity (Latin Americans, Sub-Saharan Africans, Asians, North Africans, Europeans). The outcomes were in-hospital mortality (IHM), intensive care unit (ICU) admission, and the use of invasive mechanical ventilation (IMV). Associations between ethnic groups and clinical outcomes adjusted for patient characteristics and baseline Charlson Comorbidity Index values and wave were evaluated using logistic regression. (3) Results: Of 23,953 patients (median age 69.5 years, 42.9% women), 7.0% were Latin American, 1.2% were North African, 0.5% were Asian, 0.5% were Sub-Saharan African, and 89.7% were European. Ethnic minority patients were significantly younger than European patients (median (IQR) age 49.1 (40.5−58.9) to 57.1 (44.1−67.1) vs. 71.5 (59.5−81.4) years, p < 0.001). The unadjusted IHM was higher in European (21.6%) versus North African (11.4%), Asian (10.9%), Latin American (7.1%), and Sub-Saharan African (3.2%) patients. After further adjustment, the IHM was lower in Sub-Saharan African (OR 0.28 (0.10−0.79), p = 0.017) versus European patients, while ICU admission rates were higher in Latin American and North African versus European patients (OR (95%CI) 1.37 (1.17−1.60), p < 0.001) and (OR (95%CI) 1.74 (1.26−2.41), p < 0.001). Moreover, Latin American patients were 39% more likely than European patients to use IMV (OR (95%CI) 1.43 (1.21−1.71), p < 0.001). (4) Conclusion: The adjusted IHM was similar in all groups except for Sub-Saharan Africans, who had lower IHM. Latin American patients were admitted to the ICU and required IMV more often.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.